Compare Franco-Nevada Corporation (FNV) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franco-Nevada Corporation vs Tenet Healthcare Corporation — how do they compare? Franco-Nevada Corporation trades at $236.47 (market cap $46.80B), while Tenet Healthcare Corporation trades at $271.76 (market cap $21.87B). The key difference: Franco-Nevada Corporation is far larger — about 2.1× Tenet Healthcare Corporation's market cap, and Franco-Nevada Corporation pays a 0.72% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Franco-Nevada Corporation for 0 Days and Tenet Healthcare Corporation for 16 Days on average.
| FNV | THC | |
|---|---|---|
Market Cap | $46.80B | $21.87B |
Volume | 310,692 | 717,275 |
Sector | Basic Materials | Health |
52-Week High | $280.82 | $280.77 |
52-Week Low | $183.97 | $161.37 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $45.79B | $32.95B |
Dividend Yield | 0.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.
The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.
Tenet Healthcare (THC) trades at $266.91, down 0.69% today but maintains strong technical momentum with bullish moving averages. The company demonstrates robust fundamentals with three consecutive quarterly earnings beats and impressive profitability metrics including 82.83% gross margins and 53.31% ROE. Recent news highlights continued investor interest and upcoming Q3 2026 earnings release on October 29.
THC presents a compelling investment case with attractive valuation (P/E 10.32), strong analyst support (81% buy rating), and 6.2% upside to consensus target of $283.36. Key risks include cash flow sustainability for capital return strategy and potential surgical volume pressures. The stock's combination of value pricing and growth execution supports continued upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Franco-Nevada Corporation
Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).
Read more on FNV →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
